{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-107609","form_type":"8-K","ticker":"CATX","cik":"0000728387","company_name":"Perspective Therapeutics, Inc.","filed_at":"2025-08-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:46.244227+00:00","generated_at":"2026-05-17T14:05:32.146827+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Perspective Therapeutics Q2 net loss $21.5M, EPS -$0.29; cash $192M; VMT-α-NET Cohort 3 opened","bullets":["Net loss of $21.5M ($0.29 per share) vs $11.7M ($0.18) in Q2 2024; operating expenses rose 65%.","Cash, cash equivalents & short-term investments $192M as of June 30, sufficient into late 2026.","R&D expenses $16.6M (+79% YoY) driven by clinical site activities and drug product costs.","FDA alignment obtained to open Cohort 3 (6.0 mCi) for [212Pb]VMT-α-NET; two patients dosed as of July 31.","VMT01 melanoma program: combination with nivolumab cohort opened; five monotherapy patients treated."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-107609","json":"https://secwatch.observer/filing/0000950170-25-107609.json","markdown":"https://secwatch.observer/filing/0000950170-25-107609.md","text":"https://secwatch.observer/filing/0000950170-25-107609.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/728387/000095017025107609/0000950170-25-107609-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/728387/000095017025107609/catx-20250813.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T14:05:32.146827+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}